In ovarian cancer, it has shown promise by targeting the tumor microenvironment, specifically by suppressing the polarization of macrophages into the M2 pro-tumor phenotype, a shift usually triggered by interleukin IL-4 and IL-13 exposure. This evidence concerns the gene IL13 and neoplasm.